Drug reference

Telbivudine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 681

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Chronic hepatitis B infection with compensated liver disease, evidence of viral replication, and histologically documented active liver inflammation or fibrosis, when other treatment is not appropriate ▶BY MOUTH ▶Adult: 600 mg once daily

PDF page 681

Cautions

Lamivudine-resistant chronic hepatitis B—risk of telbivudine resistance CAUTIONS, FURTHER INFORMATION Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.

PDF page 681

National Funding Access Decisions

NICE decisions ▶Telbivudine for chronic hepatitis B (August 2008) NICE TA154 Telbivudine is not recommended for the treatment of chronic hepatitis B. Patients currently receiving telbivudine can continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA154

PDF page 681

Safety

Interactions

→Appendix 1: telbivudine

PDF page 681

Side Effects

▶Common or very common Abdominal pain. cough. diarrhoea. dizziness. fatigue. headache. nausea. rash ▶Uncommon Arthralgia. malaise. muscle complaints. nerve disorders. pain. sensation abnormal. taste altered ▶Rare or very rare Lactic acidosis

PDF page 681

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 681

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

PDF page 681

Renal Impairment

Dose adjustments 600 mg every 48 hours if eGFR 30–49 mL/minute/1.73 m2; 600 mg every 72 hours if eGFR less than 30 mL/minute/1.73 m2.

PDF page 681

Monitoring Requirements

Monitor liver function tests every 3 months and viral markers of hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation.

PDF page 681

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Sebivo (Novartis Pharmaceuticals UK Ltd) Telbivudine 600 mg Sebivo 600mg tablets | 28 tablet P £290.33 ANTIVIRALS › NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS eiiii F 683

PDF page 681

Clinical care

Patient And Carer Advice

Muscle effects and peripheral neuropathy Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, or numbness, tingling or burning sensations.

PDF page 681

Dose text by age group

Adult

600 mg once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 681

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Telbivudine

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 681

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 681

Cautions

PDF page 681

National Funding Access Decisions

PDF page 681

Safety

Interactions

→Appendix 1: telbivudine

PDF page 681

Side Effects

PDF page 681

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk.

PDF page 681

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

PDF page 681

Renal Impairment

Dose adjustments 600 mg every 48 hours if eGFR 30–49 mL/minute/1.73 m2; 600 mg every 72 hours if eGFR less than 30 mL/minute/1.73 m2.

PDF page 681

Monitoring Requirements

PDF page 681

Dose and formulations

Medicinal Forms

PDF page 681

Clinical care

Patient And Carer Advice

Muscle effects and peripheral neuropathy Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, or numbness, tingling or burning sensations.

PDF page 681

Dose text by age group

Adult

600 mg once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 681

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.